MedTrace Logo

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

NCT03370835 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-12-12

No results posted yet for this study

Summary

Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Disease (COPD) and reactive airway disease, however, has been limited due to possible side effects such as worsening of lung function or increasing airway spasms and asthma attacks. The purpose of this study is to find out if patients with COPD can tolerate being on a beta-blocker at doses recommended for the treatment of heart disease conditions. This study also seeks to find out if a selective beta-1 receptor beta-blocker is better than a non-selective beta-blocker in patients with mild to moderate COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Asthma
  • Adverse Effect of Beta-adrenoreceptor Antagonists

Interventions

DRUG

Metoprolol succinate ER

Cardioselective beta-blocker

DRUG

Carvedilol

Non-cardioselective beta-blocker

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Freny V Mody, MD · VA Greater Los Angeles Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03370835 on ClinicalTrials.gov